Biogen: Incremental Pipeline Progress and Spinraza Update Support Hold Rating Amid Ongoing Uncertainties

Analyst Jason Zemansky of Bank of America Securities maintained a Hold rating on Biogen, retaining the price target of $207.00.

Jason Zemansky has given his Hold rating due to a combination of factors related to Biogen’s recent progress and remaining uncertainties. He notes that while the stock reacted positively to several constructive updates across the pipeline, these developments are incremental and do not yet justify a material change in his long-term fundamental stance or valuation framework.

He highlights encouraging phase 2 results for litifilimab in cutaneous lupus, which support the drug’s potential but still require confirmation in the pivotal phase 3 trial expected in 2027 before meaningfully changing the risk‑reward profile. In addition, the FDA’s approval of the high‑dose Spinraza regimen removes a regulatory overhang and may modestly strengthen a key franchise, yet ongoing competitive and pricing pressures are likely to drive continued revenue erosion, suggesting that additional growth catalysts are needed to warrant a more aggressive rating at this time.

According to TipRanks, Zemansky is a 5-star analyst with an average return of 23.4% and a 59.52% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as BridgeBio Pharma, Madrigal Pharmaceuticals, and Cytokinetics.